products
 
작성일 : 21-03-17
[HansaBioMed Life Sciences] SeleCTEV™ DNA Enrichment Kit
Puri cation of circulating free DNA (cfDNA) & tumor-derived EVs DNA

 

SeleCTEV™ DNA Enrichment Kit

Puri cation of circulating free DNA (cfDNA) & tumor-derived EVs DNA

 

  클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

 

SeleCTEV™ DNA Enrichment Kit allows the selective purification of circulating free DNA (cfDNA) and tumor-

derived extracellular vesicles (EVs) DNA from plasma. The isolation is based on Exosomics’proprietary

peptide affinity method. Enables better downstream analytical performance.

 

클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

   

Category:

 

Pre-analytical

Isolation method:

 

Affinity

Sample Type:

 

Human plasma, serum & urine

Sample Volume:

 

0.5 - 2mL

Reagents:

 

24

 

Applications

• Purifies and concentrates DNA from tumor-derived EVs and cfDNA from biofluids that contain low

  abundance fragmented DNA

• For any liquid biopsy sample that requires analysis of DNA at low amount allelic frequency (AF)

 

Advantages

• Highly efficient pre-analytical method to harvest tumor DNA from biofluids

• Spin column technology without use of organic solvents

• Flexible sample input

 

Mutation Recovery & Enrichment

 

클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

Mutation-bearing EVs and cfDNA were spiked alone and together into healthy donor plasma and processed

with SeleCTEV™ and Competitor Q to obtain DNA. SeleCTEV™ isolated more mutation thank Competitor Q

from both biological sources, suggesting that SeleCTEV™ is a more efficient way to isolate EVs and cfDNA

than Competitor Q.

 

Case Study: Metastatic Melanoma Patients

클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

Plasma samples were collected from twenty patients

with BRAF V600E positive tumors and thirty patients

with wild type (WT) metastatic melanoma (MM) based

on tissue biopsy examination. Five hundred microliters

of plasma were processed with SeleCTEV™ and

Competitor Q and copies of BRAV V600E and BRAF WT

were detected by digtal PCR. BRAF V600E gene copies

were detected in 11 - and 8 Competitor Q - processed

plasma samples of the mutant cohort. On average,

SeleCTEV™ isolated moremutant and WT copies than

Competitor Q.

 

 클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

SeleCTEV™ and Competitor Q were used for monitoring BRAFV600E levels in the plasma of BRAF inhibitor-

treated MM patients. In patient #1 disease progression (DP) occurred within 3 months and was associated to

rebounding levels of circulating BRAFV600E and unfavorable prognosis. In patient #2 no clinical evidence of

disease progression was observed at later time points, and mutant gene copies remained low or

undetectable in plasma.

 

 Data Sheet (PDF)

 

Ordering information

     

Catalog No.

Product Name

Size

N/A

SeleCTEV™ DNA Enrichment Kit

25 rxns

 

 

▣ 관련 페이지 ; HansaBioMed